Insmed reported a Phase 3 victory for Arikayce in treatment‑naïve patients with Mycobacterium avium complex (MAC) lung infection, meeting the trial’s primary goals and showing improved respiratory outcomes and culture conversion rates. The company said the results open the door to expanding Arikayce into earlier lines of care beyond the accelerated‑approval population it currently serves. The study, disclosed in company statements and STAT reporting, achieved prespecified endpoints for symptom improvement and microbiologic response. Arikayce was previously approved under accelerated approval for refractory MAC; the new data support broader label discussions with regulators and potential commercial upside. Analysts and management highlighted peak sales upside if Arikayce penetrates front‑line treatment, while payers and guideline groups will scrutinize comparative benefit and safety versus standard regimens.